Company Analysis Cara Therapeutics
1. Summary
Advantages
- The stock's return over the last year (462.92%) is higher than the sector average (-21.54%).
Disadvantages
- Price (5.01 $) is higher than fair price (3.21 $)
- Dividends (0%) are below the sector average (0.5351%).
- Current debt level 34.3% has increased over 5 years from 1.85%.
- The company's current efficiency (ROE=-207.61%) is lower than the sector average (ROE=9.78%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Cara Therapeutics | Healthcare | Index | |
|---|---|---|---|
| 7 days | -0.2% | -20.4% | -3.1% |
| 90 days | 44.9% | -22.2% | -6.9% |
| 1 year | 462.9% | -21.5% | 13.5% |
CARA vs Sector: Cara Therapeutics has outperformed the "Healthcare" sector by 484.46% over the past year.
CARA vs Market: Cara Therapeutics has outperformed the market by 449.42% over the past year.
Stable price: CARA is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: CARA with weekly volatility of 8.9% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (5.01 $) is higher than the fair price (3.21 $).
Price is higher than fair: The current price (5.01 $) is 35.9% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (17.73) is lower than that of the sector as a whole (57.27).
P/E vs Market: The company's P/E (17.73) is lower than that of the market as a whole (49.14).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.6346) is lower than that of the sector as a whole (4.64).
P/BV vs Market: The company's P/BV (0.6346) is lower than that of the market as a whole (3.44).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.73) is lower than that of the sector as a whole (33.44).
P/S vs Market: The company's P/S indicator (1.73) is lower than that of the market as a whole (10.29).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-0.2244) is higher than that of the sector as a whole (-17.68).
EV/Ebitda vs Market: The company's EV/Ebitda (-0.2244) is lower than that of the market as a whole (25.46).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -302.17% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-302.17%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (106.41%).
5.4. ROE
ROE vs Sector: The company's ROE (-207.61%) is lower than that of the sector as a whole (9.78%).
ROE vs Market: The company's ROE (-207.61%) is lower than that of the market as a whole (8.96%).
5.5. ROA
ROA vs Sector: The company's ROA (-94.17%) is lower than that of the sector as a whole (0.33%).
ROA vs Market: The company's ROA (-94.17%) is lower than that of the market as a whole (6.33%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-41.96%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-41.96%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5351%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Selling More insider purchases by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 04.02.2025 | Posner Christopher PRESIDENT AND CEO |
Sale | 4.72 | 1 756 | 372 |
| 01.08.2024 | Posner Christopher PRESIDENT AND CEO |
Sale | 0.35 | 1 452 | 4 149 |
| 05.04.2024 | Terrillion Scott SEC'Y; CHIEF COMPLIANCE & G.C. |
Sale | 0.83 | 2 285 | 2 753 |
| 05.04.2024 | Goncalves Joana CHIEF MEDICAL OFFICER |
Sale | 0.83 | 2 285 | 2 753 |
| 21.12.2022 | Terrillion Scott Sec'y; Chief Compliance & G.C. |
Sale | 11.27 | 28 862 | 2 561 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
